- Home
- XRTX vs FLZH Comparison
XRTX vs FLZH Comparison
Compare XRTX & FLZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XRTX | FLZH |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | XRTX | FLZH |
|---|---|---|
| Price | $2.02 | $1.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.6K | ★ 124.8K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $1.60 |
| 52 Week High | $3.60 | $2.88 |
Technical Indicators
Market Signals| Indicator | XRTX | FLZH |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 21.28 |
| Support Level | $0.37 | $1.64 |
| Resistance Level | $2.28 | $1.91 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 20.83 | 37.93 |
Price Performance
Historical ComparisonAbout XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.